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Abstract
Background: Despite diverging levels of amyloid-β (Aβ) and TAU pathology, different mouse models, as well as
sporadic AD patients show predictable patterns of episodic memory loss. MicroRNA (miRNA) deregulation is well
established in AD brain but it is unclear whether Aβ or TAU pathology drives those alterations and whether miRNA
changes contribute to cognitive decline.
Methods: miRNAseq was performed on cognitively intact (4 months) and impaired (10 months) male APPtg
(APPswe/PS1L166P) and TAUtg (THY-Tau22) mice and their wild-type littermates (APPwt and TAUwt). We analyzed
the hippocampi of 12 mice per experimental group (n = 96 in total), and employed a 2-way linear model to
extract differentially expressed miRNAs. Results were confirmed by qPCR in a separate cohort of 4 M and 10 M
APPtg and APPwt mice (n = 7–9 per group) and in human sporadic AD and non-demented control brain.
Fluorescent in situ hybridization identified their cellular expression. Functional annotation of predicted targets
was performed using GO enrichment. Behavior of wild-type mice was assessed after intracerebroventricular
infusion of miRNA mimics.
Results: Six miRNAs (miR-10a-5p, miR-142a-5p, miR-146a-5p, miR-155-5p, miR-211-5p, miR-455-5p) are
commonly upregulated between APPtg and TAUtg mice, and four of these (miR-142a-5p, miR-146a-5p, miR-
155-5p and miR-455-5p) are altered in AD patients. All 6 miRNAs are strongly enriched in neurons. Upregulating these
miRNAs in wild-type mice is however not causing AD-related cognitive disturbances.
Conclusion: Diverging AD-related neuropathologies induce common disturbances in the expression of neuronal
miRNAs. 4 of these miRNAs are also upregulated in AD patients. Therefore these 4 miRNAs (miR-142a-5p, miR-146a-5p,
miR-155-5p and miR-455-5p) appear part of a core pathological process in AD patients and APPtg and TAUtg mice.
They are however not causing cognitive disturbances in wild-type mice. As some of these miRNA target AD relevant
proteins, they may be, in contrast, part of a protective response in AD.
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Background
Declarative memory impairment (i.e. deficits in remem-
bering facts and events) is one of the most prominent
and progressive neuropsychological hallmarks of Alzhei-
mer’s disease (AD), yet it remains unknown how the
neuropathological processes in AD give rise to these
mnemonic disturbances. As genetic mutations in familial
AD patients occur only in genes linked to amyloid-beta
(Aβ) processing, a central and initiating role for Aβ has
been postulated, yet the degree of amyloidosis correlates
poorly with the extent of cognitive impairment [1]. Con-
versely, the spreading of neurofibrillary tangle (NFT)
pathology corresponds robustly with clinical AD pro-
gression [2], but no pathogenic mutations for AD have
been found in the TAU gene (MAPT) up to date.
Sporadic AD patients present with predictable patterns
of progressive declarative memory impairment, yet they
can exhibit highly divergent neuropathological profiles
with different degrees of Aβ plaque load, cerebral amyloid
angiopathy, severity of brain atrophy and degree of NFT
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formation and spread [3, 4]. Similarly, mouse models of
AD with amyloidosis profiles or TAU inclusion pathology
display overlapping profiles of hippocampus-dependent
memory deficits, including progressive declarative mem-
ory impairments [4–7]. It is noteworthy that in AD mouse
models the memory impairments are claimed to precede
or occur independently of neuron loss. These clinical and
preclinical observations suggest that despite diverging ini-
tiating factors, Aβ and TAU pathologies might converge
onto common pathways, ultimately leading to the induc-
tion of memory deficits.
Given the vast amount of literature demonstrating al-
tered microRNA (miRNA) expression in AD patients [8,
9] and their abundance in the brain and the synaptic com-
partment [10, 11], it could be assumed that miRNA de-
regulation play a central role in AD-related cognitive
impairments [12]. Whereas some miRNAs may directly
contribute to the formation of AD neuropathology by
regulating expression of key AD-related genes, such as
APP, BACE1 or MAPT [13], others regulate the synaptic
environment, by altering dendritic branching, neurite out-
growth and spine morphology [14–17]. miRNAs can be
generated in response to synaptic activity [14, 15, 18, 19]
and modulate the maintenance of long-term potentiation
[14], which is considered the neurophysiological substrate
of memory formation [20]. Obviously, it is also possible
that miRNA changes are associated with inflammatory or
other disease-related processes and it is impossible to ex-
clude a priori whether alterations in miRNA expression
have protective or disease causing effects.
The current study explores whether miRNA distur-
bances are associated with the progressive memory
impairments in AD. miRNAseq on mouse models of
amyloidosis (APPtg (APPswe/PS1L166P) [21]) and TAU
pathology (TAUtg (THY-Tau22) [22]) and their wild-type
littermates (APPwt and TAUwt), before and after the on-
set of cognitive impairments, identified six miRNAs in-
volved in neuronal and synaptic dysfunction that were
commonly deregulated, yet most strongly in APPtg mice.
A similar upregulation was confirmed for four miRNAs,
i.e. miR-142a-5p, miR-46a-5p, miR-155-5p and
miR-455-5p in AD brain. Despite the clear correlation
with disease progression, we could not establish an un-
equivocal link between changes in miRNA level and cog-
nitive behavior in wild-type mice. Therefore, these
miRNA are likely not directly causative to cognitive de-
cline in AD. We discuss alternative possibilities how
these miRNA could be involved in AD.
Methods
Mice
All animal experiments were conducted according to
protocols approved by the local Ethical Committee of
Laboratory Animals of the KU Leuven (governmental
licence LA1210591, ECD project number P202–2013)
following governmental and EU guidelines. APPtg
(APPswe/PS1L166P [21]) mice express APPSwe and
PSEN1L166P transgenes under the Thy1.2 promoter;
TAUtg (THY-Tau22 [22]) mice, express the 412 aa iso-
form of the human 4-repeat MAPT gene containing the
G272 V and P301S mutation under the Thy1.2 promoter.
All mice have been backcrossed to C57BL/6 J for more
than 9 generations. Male mice (transgenic (tg) and
wild-type (wt) littermate controls) were sacrificed at
4 months (4 M, average 123.8 days, SD 1.84 days) or
10 months of age (10 M, average 299.8 days, SD
2.22 days), giving rise to 8 experimental groups (n = 12
per group): APPwt 4 M, APPwt 10 M, APPtg 4 M,
APPtg 10 M, TAUwt 4 M, TAUwt 10 M, TAUtg 4 M,
TAUtg 10 M. An independent cohort of 4 M and 10 M
APPtg and APPwt littermates (n = 7–9/group) was used
for qPCR validation. Following cervical dislocation, both
left and right hippocampi were microdissected and
snap-frozen in liquid nitrogen. Samples were stored at
-80 °C.
Human samples
Hippocampal tissue samples were obtained from the
London Neurodegenerative Diseases Brain Bank and col-
lected in accordance to British legislation and their eth-
ical board [23]. The human study was evaluated and
approved by the ethical committees of Leuven University
and UZ Leuven [23].
RNA extraction
The left hippocampus was homogenized in TRIzol (Invi-
trogen, Carlsbad, CA, USA) using 1 ml syringes and
22G/26G needles and purified on mirVana spin columns
according to the manufacturer’s instructions (Ambion,
Austin, TX, USA). RNA purity (260/280 and 260/230 ra-
tios) and integrity was assessed using Nanodrop ND-
1000 (Nanodrop Technologies, Wilmington, DE, USA)
and Agilent 2100 Bioanalyzer with High Sensitivity chips
(Agilent Technologies, Inc., Santa Clara, CA, USA) and
Qubit 3.0 Fluorometer (Life Technologies, Carlsbad, CA,
USA), respectively (see Additional file 1: Table S1).
Library construction, sequencing and mapping
The miRNA library was prepared by the Genomics Core
(UZ Leuven) using Illumina TruSeq Small RNA Sample
Prep Kit (Illumina, San Diego, CA, USA), adding 2 μl of
50% PEG8000 in the 3′ ligation and with 13 cycles of
cDNA amplification. Library construction of 96 samples
was performed in 4 different batches of 24 samples, with
1–5 samples per experimental group within each batch.
Three libraries were pooled and all RNAs between 5 and
40 bps in length were selected using the BluePippin (Sage
Science, Beverly, MA, USA). Equimolar concentrations of
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8 pools of 3 samples were loaded per lane and 4 lanes in
total were used to sequence 50 bps single-end reads using
the Illumina HiSeq 2500 (Illumina, San Diego, CA, USA).
Raw reads were trimmed with Flexbar (version 2.5.35,
[24]) and filtered to remove unwanted adaptors, low-
quality reads and reads with ambiguous nucleotides.
Reads with ≥15 nucleotides were mapped to the mm10/
GRCm38 Mus musculus assembly using Bowtie2 (ver-
sion 2.2.1, [25]) allowing 1 mismatch. Stranded miRNA
read counts were produced by FeatureCounts from the
Subread package (version 1.4.4, [26]) using the miRBase
gff3 annotation file (version 20, [27]).
Data pre-processing and differential expression analysis
We found in 2 of the 12 mice in the APPtg 10 M group
a 46% lower expression levels of hsa-APPswe, a 26%
lower expression of hsa-Psen1L166p and a 24% reduc-
tion in mmu-Thy1 gene, whose promoter drives the ex-
pression of the transgenes, compared to the other APPtg
10 M mice. In the absence of an explanation, these two
mice were excluded from all further analyses (data not
shown).
miRNAs with an average of raw read counts < 5 were
discarded, leaving 644 miRNAs for differential expression
(DE) analysis. Non-biological variation was removed by
the removeBatchEffect function from limma package
3.22.7 Bioconductor/R [28], preserving biological variation
of genotype, age and their interactions in a generalized lin-
ear model for the APPtg and TAUtg dataset combined, as
well as separately, while removing technical effects such
as batch effect, RNA extraction group effects, RNA con-
centration effects. DE analysis was conducted using a
2-way interaction model (age, genotype, age*genotype)
and performing Benjamini-Hochberg p-value adjustment
for multiple testing. All miRNAseq data has been submit-
ted to the GEO database under accession number
GSE110743.
Functional assessment of miRNA targets
Predicted miRNA targets were obtained from TargetScan
Mouse v7.1. Gene Ontology (GO) category overrepresen-
tation among predicted targets for each upregulated
miRNA was assessed using the unranked option in
GOrilla [29]. Only GO categories with > 5 predicted tar-
gets overlapping were considered for the analysis, using
FDR-corrected p-value < 0.05 for significance.
Reverse transcription and real time PCR
One hundred ng of RNA was used for reverse transcrip-
tion of miRNAs using the miRCURY LNA™ Universal
cDNA synthesis kit II (Exiqon, Denmark). Real time
semi-quantitative PCR used ExiLENT Sybr Green mas-
ter mix kit and LNA PCR primers (Exiqon, Denmark).
Cp (crossing points) were determined by using the
second derivative method. Fold changes were calculated
with the ΔΔCt method (Livak & Schmittgen, 2001) using
the geometric mean of mmu-let7g-5p and mmu-miR-
23b-3p as normalizer.
Protein extraction, ELISA, western blotting and
correlation analyses
The right hippocampi (n = 5–6/group) of our miRNA-
seq mouse samples were homogenized using a mechan-
ical homogenizer, Fastprep tubes and T-PER Tissue
Protein Extraction Reagent (#78510, Thermo Fisher
Scientific, Belgium) with phosphatase (P0044 and
P5726, Merck, Germany) and cOmplete protease inhib-
itors (#11836145001, Roche/Merck, Germany). The sol-
uble proteins were separated from the insoluble pool by
collecting the supernatant after ultracentrifugation (1 h,
4 °C, 55000 rpm; TLA 100.4 rotor, Beckman Coulter,
France). For insoluble Aβ extraction, the pellet was re-
suspended in 2 volumes (vol: wet weight of tissue) of
GuHCl (6 M GuHCl/50 mM Tris-HCl, pH 7.6) with
cOmplete protease inhibitors and sonicated for 30s.
After 1 h incubation at 25 °C and ultracentrifugation
(20 min, 70.000 rpm, 4 °C; TLA 100.4 rotor, Beckman
Coulter, France), the supernatant is diluted 12× in
GuHCl diluent buffer (20 mM phosphate, 0.4 M NaCl,
2 mM EDTA, 10% Block Ace, 0.2% BSA, 0.0% NaN3,
0.075% CHAPS, pH 7.0) with cOmplete protease inhib-
itors. Both soluble and insoluble protein fractions were
used for detection of human Aβ40 and Aβ42 by stand-
ard sandwich ELISA as described before [30].
For detection of total and phosphorylated TAU, the sol-
uble protein fractions were diluted in 1× SDS-PAGE load-
ing buffer with 5% β-mercaptoethanol, boiled (5 min at
96 °C) and briefly centrifuged. Electrophoreses was per-
formed with 7.5 μg (total TAU) or 15 μg (phosphorylated
TAU) of protein on NuPAGE Novex 4–12% Bis-Tris gels
(Life Technologies, Thermo Fisher Scientific, Belgium),
and after transfer, nitrocellulose membranes were blocked
for 1 h in blocking solution (5% milk powder in 0.1%
TBS-Tween20). Antibody incubation was performed in
blocking solution; for the primaries (mouse TAU-5 (total
TAU, 1/1000; Ab80579, Abcam, UK); AT8 (1/500;
MN1020) and AT270 (1/500; MN1050, Pharmingen, BD
Biosciences, Belgium); β-actin (1/100.000; A5441, Sigma-
Aldrich, Belgium)) overnight at 4 °C, and for the second-
ary (goat anti-mouse, 1/10.000; 170–6516, Bio-Rad, USA)
for 1 h at room temperature. Blots were developed using
chemiluminescence (Perkin Elmer, USA) and normalized
to β-actin expression.
Given that not all data was normally distributed,
Spearman correlation analysis and False Discovery Rate
(FDR) p-value adjustment (padj) was performed between
the mouse miRNAseq-derived and normalized miRNA
expression values, ELISA-based soluble and insoluble
Sierksma et al. Molecular Neurodegeneration  (2018) 13:54 Page 3 of 15
human Aβ40 and Aβ42 levels and immunoblotting-
based total TAU and phosphorylated TAU levels. The
same was done for the human qPCR-based miRNA ex-
pression values (this study) and the immunoblotting-
based levels of total TAU, AT8, AT270, full length APP,
soluble APPβ, and APP C-terminal fragments (CTFs) in
the same samples, which were analyzed in a previous
study [31].
In situ hybridization for miRNAs and immunofluorescence
In situ hybridization (ISH) probes (Ribotask and Exiqon,
Denmark) against the mature sequence of miRNAs [32–
34] were used (Additional file 1: Table S1). Slices
(50 μm) of 4% paraformaldehyde perfused mouse brain
(APPtg 4 M, APPtg 10 M, APPwt 4 M, APPwt 10 M)
were mounted, dried at room temperature (RT), post-
fixed with 4% ice-cold paraformaldehyde, heated 3× to
boil in the microwave in sodium citrate buffer (10 mM,
0.05% Tween 20, pH 6.0), washed in methylimidazole
buffer (2 × 10 min; 0.13 M 1-methylimidazole, 300 mM
NaCl, pH 8.0) and fixed with EDC (0.16 M, pH 8.0) in
methylimidazole buffer for 1.5 h at 25 °C in a humidified
chamber using hybridization covers. After PBS washes,
slides were acetylated (1 min, RT) and pre-hybridized
(1 h) in hybridization solution (50% formamide, 5xSSC,
1× Denhardt’s solution and 500 μg/ml yeast t-RNA for
Ribotask probes). miRNA or scrambled probes (40 nM)
were linearized in hybridization buffer (4 min, 94 °C).
Sections were hybridized (1.5 h, for temperature see
Additional file 1: Table S1). Following stringency washes
(at hybridization temperature: 3 × 0.2xSSC and 1 ×
0.5xSSC; at RT 1× 2xSSC), slides were incubated with
3% H2O2 (7 min, RT), and in blocking buffer 1 (1 h, RT;
0.1 M Tris-HCl, 0.15 M NaCl, 0.5% Blocking Reagent
(Roche Diagnostics, Belgium) and 0.5% BSA). Subse-
quently, sections were incubated (1 h, RT) with anti-
fluorescein HRP-conjugated antibody (Roche Diagnos-
tics, Belgium) in blocking buffer 1 and developed with
TSA Plus Fluorescein reagent (8 min, RT; Perkin Elmer,
USA).
Antibodies 6E10 (1/150, Biolegend, USA, #803002),
GFAP (1/200, Dako-Agilent, USA, #Z033401) were
used for immunofluorescence. Sections were blocked
with blocking buffer 2 (1 h, RT; 5% normal goat serum
in 0.2% PBS-TritonX 100). Primary antibodies were in-
cubated overnight at 4 °C (6E10) or for 2 h (GFAP) at
RT in incubation solution (0.5% goat serum in 0.2%
PBS-T), followed by incubation with the secondary
antibody (2 h, RT). DAPI counterstain (10 min, RT; 1/
5000, Sigma-Aldrich, Belgium, #D9542) was per-
formed and mounting was carried out in mowiol. Im-
ages (z-stacks) were acquired using a Nikon A1R
Eclipse Ti confocal microscope.
Intracerebroventricular injections and behavioral
experiments
Male mice (C57BL/6 J, 18–26 weeks old, n = 9–12 per
treatment group) were implanted with a guide cannula
in the lateral ventricle (from bregma AP: − 0.1 mm,
ML: − 1.0 mm, DV: − 3.0 mm) under isoflurane
anesthesia (5% induction, 2–2.5% maintenance). Mice
were infused 1× per week with 2 μl of miR-mimic or
negative control oligonucleotide (mature sequence,
based on C. elegans cel-miR-67: UCACAACCUCCUAG
AAAGAGUAGA (miRbase ID: MIMAT0000039) Dhar-
macon, GE Healthcare, Belgium) mixed in a 1:1 ratio
with lipofectamine 2000 (Thermo Fischer Scientific,
Belgium).
A titration experiment (n = 2 per dose) was performed
to determine an adequate dose of miR-mimic infusion
(Dharmacon, GE Healthcare, Belgium), i.e. not exceeding
100-fold overexpression after 1 week of infusion (see
Additional file 2: Figure S1). MiR-mimic treated mice
were sacrificed either 1 week or 48 h after infusion via
cervical dislocation and the expression levels of the ap-
propriate miRNA were assessed in the right hippocam-
pus using semi-quantitative PCR (see above). The degree
of miRNA overexpression in the miR-mimic treated
mice was expressed as fold change compared to equimo-
lar or higher concentrations of negative control-treated
mice (i.e. 150 pmol miR-mimic against 150 pmol con-
trol; 75 & 15 pmol miR-mimic against 75 pmol control;
1.5 to 0.0015 pmol miR-mimic against 1.5 pmol control
oligonucleotide).
For the behavioral experiments mice were subjected to
either 3wks (individual miRNAs) or 7 wks (miR-mix) of
miR-mimic overexpression followed by behavioral as-
sessment (see Fig. 4a), splitting the mice over four separ-
ate batches of behavioral experiments: miR-142a
(15 pmol) vs negative control (15 pmol); miR-146a
(15 pmol) & miR-155 (1 pmol) vs negative control
(15 pmol); miR-10a (0.1 pmol), miR-211 (0.1 pmol) &
miR-455 (0.15 pmol) vs negative control (0.15 pmol);
miR-mix (31.35 pmol) vs negative control (31.35 pmol).
Behavioral assessment was performed using the open
field, T-maze, context- and cue-dependent fear condi-
tioning, Morris Water Maze (MWM), novel object rec-
ognition (NOR) and social preference/social novelty test
(SPSN). Mice were sacrificed by cervical dislocation
7 days after the last injection and hippocampi were dis-
sected, snap frozen and stored at − 80 °C, before pro-
cessing samples for semi-quantitative PCR (see above).
Locomotion and anxiety-like behavior
After 30 min dark adaptation, the mouse was placed in a
brightly lit (465 lx) 50 × 50 cm square arena of transpar-
ent plexiglass, 1 min habituation and 10 min recording
[35]. Mice were tracked in the arena with ANY-mazetm
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Video Tracking System software (Stoelting Co., IL,
USA), recording total path length (locomotor behavior)
and time spent and number of entries in the corners
(7 × 7 cm), walls and center circle of the open field
(anxiety-like behavior).
Spatial working memory
The mouse was placed in the start arm of the T-maze
and free to enter the left or right arm (familiar arm),
after which the other arm (novel arm) was blocked.
After 30 min, the mouse was re-introduced into the
maze with all arms accessible, and the total path length,
number of entries and total time spent in each arm was
recorded using ANY-mazetm software.
Fear conditioning
Mice were habituated to the contextual fear response
(CFR) cage (StartFear cage, Panlab, Cornella de Llobre-
gat, Spain) for 5 min. Context- and cue-dependent fear
conditioning was induced on day 2 by presenting 2 con-
ditioned stimuli (i.e. 30s tone, 4 kHz, 80 dB, inter-stimu-
lus interval 1 min) which co-terminated with a 2 s
0.3 mA foot shock [36]. Freezing behavior was recorded
24 h later (sensitive Weight Transducer System (Panlab,
Cornella de Llobregat, Spain)) as a proxy for memory re-
tention in the conditioned context (no lights, grid floor,
ethanol-based odor for 5 min), and in a novel context
(lights on, white plastic floor and mint odor, 3 min) and
in combination with the auditory cue (3 min).
Spatial learning
Mice were trained for 2 × 5 days in a 150 cm circular
Morris water maze (MWM) pool filled with opaque
(non-toxic white paint) water (26 °C) [35], where a
15 cm round platform was submerged in a fixed position
1 cm below water level. Daily training session consisted
of 4 trials (15-30 min intervals) starting from 4 random-
ized starting positions. Mice that failed to locate the
platform within 2 min, were gently guided to the plat-
form and left there for 10s. Probe trials were conducted
on day 6 and 12 during the 10-day training period,
where the platform was removed from the pool and
mice swam freely for 100 s. ICV injections were admin-
istered after the probe trial. Mice were tracked with
EthoVision tracking equipment and software (Noldus,
Wageningen, the Netherlands), calculating escape la-
tency, path length and swimming velocity during train-
ing, and, during the probe trial, time spent in each
quadrant and latency to first enter the target quadrant
and target position.
Recognition memory
In the novel object recognition (NOR), mice were pre-
sented for 10 min with 2 randomized identical objects
(blue or yellow LEGO® blocks built in different ways, a
liquid filled 50 ml falcon tube or a Playmobil® Christmas
tree) placed 10 cm from the corners on the diagonal line
of the open field arena. After 1 h, the left or right object
was replaced by a different object. Exploration lasted
5 min and was scored manually for each object, being
defined as directing its nose to the object (< 1 cm dis-
tance) and/or touching the object with its nose. Memory
performance was calculated by the D2 discrimination
index: (time spent exploring novel object – time spent
exploring the familiar object)/ total time spent exploring
both objects [37].
Sociability/preference for social novelty test
Sociability and social memory were assessed in the social
preference/social novelty test (SPSN), as described in [38].
In short, a test mouse was placed in the middle compart-
ment of a 3-compartment transparent Plexiglas arena
(94x28x30 cm), divided by manually guided sliding doors.
After 5 min habituation, a stranger mouse was placed in a
cylindrical cup in the left or right compartment, and the
test mouse could explore all 3 compartments for 10 min
during this sociability trial. Subsequently, during the social
novelty test a second stranger mouse was placed in a cy-
lindrical cup in the free compartment (left or right) and
the test mouse could again explore all 3 compartments for
10 min. Using nose tracking and a virtual 5 cm perimeter
around the cylindrical cups holding the stranger mouse,
social exploration and distance travelled was assessed
using ANY-mazetm software.
Results
Hippocampi from APPwt, APPtg, TAUwt and TAUtg
mice were harvested at 4 months (4 M) and 10 months
(10 M) of age, yielding 8 experimental groups. At 4 M
APPtg mice show modest levels of soluble and insoluble
Aβ40 and Aβ42, which drastically exacerbates at 10 M
of age (see Additional file 3: Fig. S2A), which is in line
with earlier reports [21]. Although TAU tangle-like path-
ology does not occur until 12 M in TAUtg mice, levels
of total TAU and phosphorylated TAU are similarly in-
creased in 4 M and 10 M mice compared to TAUwt
mice, as measured by AT8 and AT270 (see Additional
file 3: Figure S2C-E). Both mouse models do not demon-
strate hippocampal deficits at 4 M [5, 21, 22], yet display
very similar hippocampus-dependent memory deficits at
10 M [5].
By using http://scotty.genetics.utah.edu [39] and hu-
man AD brain miRNAseq data [40] as pilot data, we cal-
culated that n = 12/group and 7 million reads/sample
would enable us to detect 55% of miRNAs with a signifi-
cant (p < 0.05) 1.3 fold change and > 75% of miRNAs
with 1.5 fold change (p < 0.05). miRNAseq was therefore
performed on 96 hippocampal samples (see Fig. 1a for a
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Fig. 1 Deregulated miRNAs in hippocampus of APPtg and TAUtg mice and human AD patients. a) Experimental design for sequencing using
n = 12 per experimental group. b) Explanation of the 2 × 2 linear model, where those cells labeled with 1 are compared to the cells labeled with
0. In the age comparison, miRNA expression in all 10 month old (M) mice is compared to all 4 M mice. In the genotype comparison, miRNA
expression in all transgenic (TG) mice is compared to all wild-type (WT) mice. In the age*genotype comparison, we assess which miRNAs are
differentially expressed in the 10 M TG mice compared to all other groups. c) The 8 selected miRNAs that became significantly deregulated (FDR-
corrected p-value< 0.05) in the miRNAseq experiment with increasing pathology and cognitive impairment (age*genotype effect) in APPtg and
TAUtg mice combined with more than 20% change. d) Validation of 8 deregulated miRNAs in a new cohort of APPtg and APPwt mice at 4 M
and 10 M using qPCR (n = 7–9/group), expressed relatively to the 4 M WT mice. Significant age*genotype interaction effects were found for miR-
142a-, miR-146a-, miR-155-, miR-211- and miR-455-5p, with the 10M TG mice being significantly different from the other 3 groups in Tukey’s post
hoc test (**, p < 0.01; ***, p < 0.001). For miR-10a, significant main effects for age and genotype were found, but no significant age*genotype
interaction. miR-451a and miR-301b-3p remained unchanged. e) qPCR expression of the 6 validated miRNAs in hippocampus of AD patients and
non-demented (ND) controls, demonstrating significant differences for hsa-miR-142-, −miR-146a-, −miR-155- and -miR-455-5p, whereas hsa-miR-
10a-5p was too lowly expressed for qPCR assessment (t-test with Benjamini-Hochberg p-value adjustment; *, p < 0.05; ***, p < 0.001)
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schematic representation of the workflow), yielding on
average 7.7 million raw reads per sample. Raw reads
were mapped back to 644 miRNAs, discarding lowly
expressed miRNAs (≤ 5 raw counts across 10 samples).
We studied alterations in miRNA expression patterns
by using a 2 × 2 linear model (see Fig. 1b). Through this
model we can assess the effects of age, genotype and the
age*genotype interaction. The age comparison identifies
which miRNAs are differentially expressed between 4 M
and 10 M old mice, irrespective of the genotype. In the
genotype comparison, we identify which miRNAs are
different between WT and TG mice, irrespective of age.
In the age*genotype interaction comparison we assess
which miRNAs are changed with aging but that are
unique to the TG mice only. The latter thus provides
insight on miRNA alterations that correlate with the es-
tablishment of cognitive impairments and the progres-
sion of AD pathology in TG mice.
miRNAs are progressively deregulated in the
age*genotype interaction
Overall, the significant (adjusted p-value after false dis-
covery rate correction (padj) < 0.05) observed changes in
miRNA expression are modest (log2-fold change (LFC):
− 0.95 - + 2.23), similar to what we reported in AD pa-
tients [40]. Combining the APPtg and TAUtg dataset
during differential expression analysis highlights miR-
NAs that are commonly deregulated. Eight miRNAs are
significantly up-regulated with more than 20% change
(LFC > 0.26) in the age*genotype interaction when both
APPtg and TAUtg mice are taken together, although the
pattern of deregulation of miR-451a and miR-301b-3p is
less outspoken compared to the other six (see Fig. 1c).
miR-10a-5p (LFC: + 0.76), miR-155-5p (LFC: + 1.04) and
miR-211-5p (LFC: + 1.02) show the highest up-regula-
tion (see Fig. 1c and Additional file 1: Table S2). Nine
out of these 13 miRNA were previously found
up-regulated in post mortem AD brains compared to
controls [9, 40–46]. Remarkably, no significantly down-
regulated miRNAs are observed in the analysis of the
two genotypes combined.
The strongest effect appears in APPtg mice in the
age*genotype interaction resulting in 18 miRNA that are
significantly differentially expressed (Additional file 4:
Figure S3). Four out of these 18 miRNAs are also signifi-
cantly differentially expressed due to genotype alone in
APPtg mice (miR-211-5p, miR-142a-5p, miR-146a-5p
and miR-301b-3p; Fig. 1c). This indicates that their ex-
pression is already profoundly affected at 4 M of age and
their deregulation exacerbates at 10 M in APPtg.
Although 6 out of the 8 miRNA derived from the
combined genotype*age interaction (see Fig. 1c) show a
similar trend in the TAUtg-specific analysis compared to
the APPtg-specific analysis (Fig. 1c and Additional file 1:
Table S2), the overall deregulation of miRNAs is rather
subtle in the TAUtg model, with no miRNAs reaching
significance in the age*genotype comparison.
A stronger genotype effect in TAUtg mice
When comparing the effect of transgene expression
alone in the combined APPtg and TAUtg data set, 23
miRNAs are affected in a statistically significant manner
(padj < 0.05, see Additional file 4: Figure S3), but effect
sizes are modest with maximal changes for miR-146a-5p
(LFC: + 0.36) and miR-147-3p (LFC: + 0.34), or miR-
451a (LFC: − 0.40) and miR-301b-3p (LFC: − 0.27). By
assessing the transgene effects in APPtg and TAUtg mice
separately, it becomes clear that TAUtg mice have more
significantly differentially expressed miRNAs than the
APPtg mice (24 vs 6 miRNAs; padj< 0.05), although the
effects are weak. Not only do TAUtg mice display more
down-regulated miRNAs (n = 19, LFC: -0.74 to − 0.14,
for instance miR-487b-5p and miR-451a) than APPtg
mice (n = 1, miR-301b-3p, LFC: − 0.32), their LFCs are
also more pronounced. Conversely, TAUtg and APPtg
mice both show 5 significantly up-regulated miRNAs
(APPtg, LFC: + 0.23 to + 0.63, including miR-211-5p and
miR-146a-5p; TAUtg, LFC: + 0.14 to + 0.31, including
miR-7b-5p and miR-344d-3p), although the extent of
up-regulation is more pronounced in APPtg mice, and
there is no overlap in affected miRNAs.
Aging-induced miRNA changes
Assessment of the effects of aging (comparing 4 M to
10 M mice) in APPtg and TAUtg mice combined, results
in 50 significantly differentially expressed miRNAs (padj
< 0.05; see Additional file 4: Figure S3). The most
strongly up-regulated “age associated” miRNAs include
miR-193a-3p (LFC: + 0.25) and miR-16-1-3p (LFC: +
0.22) and the most strongly down-regulated miRNAs in-
clude miR-298-3p (LFC: − 0.92), miR-296-5p (LFC: −
0.78) and miR-296-3p (LFC: − 0.65).
When assessing APPtg and TAUtg mice separately,
aging induces slightly more significantly differentially
expressed miRNAs in TAUtg than in APPtg mice (30 vs
23, padj< 0.05). Aging is expected to produce similar
miRNA changes among the two different transgenes,
and we find 8 down-regulated miRNAs (including miR-
298-3p (APPtg LFC: − 0.95; TAUtg LFC: − 0.90) and
miR-296-5p (APPtg LFC: − 0.76; TAUtg LFC: − 0.80))
and 1 miRNA up-regulated (miR-210-3p (APPtg LFC:
0.14; TAUtg LFC: 0.23)) in both models. Overall, aging
induces moderate changes in miRNA expression that are
similar among APPtg and TAUtg mice.
To summarize, we can conclude that APPtg and TAUtg
transgenes induce transgene-specific and transgene-indis-
tinct changes in miRNA networks. Transgene-specific al-
terations can occur due to the distinct nature of the
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mouse models’ pathology, and it is therefore highly intri-
guing to find overlaps. These overlaps may contribute to
shared features in the phenotypes of both mouse models,
for instance the shared cognitive phenotype as previously
described [5, 21, 22]. We focus our study further on the 8
miRNAs discussed above that show a significant age*gen-
otype effect (padj< 0.05) when combining the APPtg and
TAUtg datasets (i.e. commonly deregulated) and show
more than 20% change (i.e. LFC > + 0.26 or LFC < − 0.32;
see Fig. 1c).
Confirmation of changes in a separate cohort of APPtg
mice and in AD patients
It is important to corroborate changes in miRNA ex-
pression by independent methods [40]. We therefore
measure expression of the eight selected miRNAs in an
independent new cohort of APPtg mice using semi-
quantitative qPCR. The changes in miR-301b-3p and
miR-451a, in APPtg mice as mentioned above were
small and could not be confirmed using qPCR in the
new APPtg cohort (Fig. 1d). However, the age*genotype
interaction effect for miR-142a-5p, miR-146a-5p, miR-
155-5p, miR-211-5p and miR-455-5p (p < 0.01; Fig. 1d)
is confirmed in the new cohort. miR-10a-5p shows sig-
nificant main effects for age and genotype, but not for
the age*genotype interaction. Thus, the qPCR confirms
that miR-10a-5p, miR-142a-5p, miR-146a-5p, miR-155-
5p, miR-211-5p and miR-455-5p are truly upregulated in
10 M APPtg mice.
We next analyze the expression of the human homo-
logues of the 6 verified miRNAs in hippocampal material
from 28 neuropathologically verified AD patients and 20
non-demented control cases, previously used in [31].
Semi-quantitative qPCR data indicates increased miRNA
expression in AD cases of hsa-miR142-5p (+ 72%), hsa-
miR-146a-5p (+ 26%), hsa-miR-155-5p (+ 78%) and hsa-
miR-455-5p (+ 54%; see Fig. 1e). Hsa-miR-211-5p shows
too much variability across the samples, and therefore
its alteration in human patients cannot be confirmed.
Hsa-miR-10a-5p is too lowly expressed in human hippo-
campal tissue to be detected (qPCR cycle threshold >
35). We can conclude that miR-142a-5p, miR-146a-5p,
miR-155-5p and miR-455-5p are upregulated in both
mouse models of neurodegeneration (albeit more
strongly in APPtg mice), in an independent cohort of
APPtg mice, and in AD patients, whereas the increase in
miR-10a-5p and miR-211-5p expression is only found in
the APPtg mouse model for AD.
We further assessed whether the increase in miRNA
expression was correlated to levels of pathology in both
the mouse models of neurodegeneration and in sporadic
AD patients. Spearman correlation and FDR p-value ad-
justment was performed on the miRNAseq-based ex-
pression of the 6 miRNAs and levels of soluble and
insoluble Aβ40 and Aβ42 in APPtg mice and the levels
of total TAU and phosphorylated TAU (AT8 and AT270
staining) in TAUtg mice. High (0.97<R > 0.58) and sig-
nificant (padj< 0.005) correlations are found between all
Aβ species and the miRNAs of interest in the amyloid-
osis mouse model (see Additional file 3: Figure S2B. By
contrast, significant correlations could only be found be-
tween total TAU and miR-155-5p and miR-455-5p and
between TAU Thr181 phosphorylation (AT270) and
miR-146a-5p and miR-155-5p in the tauopathy mice (see
Additional file 3: Figure S2E). In human samples, correl-
ating protein levels of TAU, AT8, AT270, full length APP,
soluble APPα and APP c-terminal fragments, as measured
in [31], with the qPCR-based expression levels of the 5
expressed miRNAs, demonstrated that miR-155-5p is also
significantly and positively correlated (R = 0.51, padj<
0.01) with levels of TAU Thr181 phosphorylation (AT270;
see Additional file 3: Figure S2F).
Deregulated miRNAs are predominantly expressed in
neurons and can regulate neuronal functions
The two major cellular alterations in the mouse models
used here are gliosis and loss of synapses and/or neu-
rons [21, 22]. We therefore used fluorescent in situ
hybridization (FISH) to find out in which cells the iden-
tified miRNAs are expressed. Five out of six miRNAs
(miR-10a-5p, miR-146a-5p, miR-155-5p, miR-211-5p,
miR-455-5p) are expressed predominantly in neurons,
as shown by the clear binding of miRNA probe within
the neuronal layers of the hippocampus (see Fig. 2).
Specific miR-142a-5p FISH signal (i.e. different from
scrambled probe) is not achieved in our hands, al-
though this miRNA displays a predominant neuronal
expression in Simian monkey brain [34]. Very little to
no FISH-positive signal is observed in Gfap-positive as-
trocytes (see Fig. 2) or Iba1-positive microglia for all 5
miRNAs (data not shown). Thus, our data suggests that
the 5 miRNAs, and likely miR-142a-5p, are mostly
expressed in neurons.
We identified their predicted targets by TargetScan
Mouse v7.1, [47] (see Additional file 1: Table S3 for an
overview). Predicted targets of 5 miRNAs (miR-455-5p
did not show significant enrichment (FDR-adjusted
p-value < 0.05) of gene ontology (GO) categories), demon-
strate significant enrichment for GO categories as ‘Regula-
tion of neurogenesis’ (GO: 0050767), ‘Signal transduction’
(GO: 0007165) and ‘Regulation of dendritic spine develop-
ment’ (GO: 0060998; see Fig. 3). Targets of miR-155-5p
also enrich significantly for immune-related GO categor-
ies, among which ‘Regulation of immune system process’
(GO: 0002682), ‘T cell activation’ (GO: 0042110), ‘T cell
differentiation’ (GO: 0030217) and ‘Regulation of myeloid
cell differentiation’ (GO: 0045637), most probably due to
its reported immune-related function in myeloid cells
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[48]. However, the importance of this for the alterations in
our mouse models is unclear given the high expression of
this miRNA in neurons (see Fig. 2).
Overexpression of miRNAs in wild-type mice does not
induce cognitive impairments
Given that the upregulated miRNAs mainly target neur-
onal and synaptic transcripts, we wondered whether up-
regulation of these miRNAs would be sufficient to induce
the cognitive alterations observed in APPtg and TAUtg
mice [5, 21, 22]. We implanted intracerebroventricular
guide cannulas into male C57BL/6 J mice (18–26 weeks of
age, n = 9–12 per treatment group) and injected weekly a
miR-mimic oligonucleotide to overexpress the 6 miRNAs
individually or in a mix combining all 6 miR-mimics
(miR-mix), or equimolar negative control oligonucleotide,
to assess their impact on cognition (see Fig. 4a). Overex-
pression of one miRNA did not lead to overexpression of
any of the other 5 miRNAs (data not shown). The
miR-mix treated mice underwent a more extensive cogni-
tive test battery (see Fig. 4a).
Weekly ICV injections of individual miR-mimics or
miR-mix leads to a significant increase in the hippocam-
pal expression of each miRNA (see Fig. 4b). miRNA
overexpression is well tolerated, with no signs of height-
ened anxiety or altered locomotor behavior as shown by
the open field test (see Additional file 5: Figure S4A, B).
However, none of miR-mimic treatments significantly
Fig. 2 Deregulated miRNAs are expressed in neurons. Fluorescent in situ hybridization of 5 deregulated miRNAs combined with a nuclear counterstain
(DAPI) and immunofluorescence for activated astrocytes (GFAP) in 10 M APPtg mice. A) All miRNA probes (rows) demonstrate high expression
in hippocampal neuronal layers, except for the scrambled probe. Scale bar, 50 μm. A’) higher magnification of the yellow box indicated in A,
demonstrating little expression of miRNA ISH probes in GFAP-positive cells. Scale bar, 100 μm
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affect cognitive behavior, as measured by the ability to
recognize the familiar arm in the T-maze (Additional file
5: Figure S4C), or freezing behavior when presented with
the same context or the cued tone that was previously
coupled to the shock in the contextual fear condition-
ing paradigm (see Fig. 4c-e, f ). MiR-mix treatment is
also not able to induce changes in spatial learning (Fig.
4g), nor in the ability to locate the hidden platform in
the Morris Water Maze after 10 days of training (see
Additional file 5: Figure S4D). Although both control-
treated and miR-mix-treated mice are unable to distin-
guish the novel stranger from the familiar stranger
mouse in the Social Preference/Social Novelty test (see
Additional file 5: Figure S4E), their ability to distinguish
a familiar and novel object remains intact (see Add-
itional file 5: Figure S4F). Overall, these results indicate
that overexpression of the 6 deregulated miRNAs does
not induce robust cognitive impairments in C57BL/6
mice.
Discussion
The current study provides a detailed outlook on the de-
regulation of the miRNA landscape in APPtg and TAUtg
mice during pathology progression and neurodegeneration-
related memory impairments and confirms 4 of the 6 iden-
tified miRNA changes in human brain. By using an unpre-
cedented number of mice per group (n = 12/group) and
highly homogeneous groups in terms of sex and age, our
statistical power is strong enough to detect even subtle
changes in miRNA expression with high confidence.
By performing a side-by-side comparison of APPtg
and TAUtg mice we have identified that overexpression
of TAU is sufficient to drive miRNA changes from 4 M
of age, while miRNA disturbances in APPtg mice mainly
occur as amyloid neuropathology has accumulated at
10 M of age. Although TAU can interact directly with
RNA and RNA binding proteins [49–51], it remains un-
clear to date whether TAU plays a direct role in miRNA
biogenesis [52] or whether our observed changes in
miRNA expression in TAUtg mice are a secondary
consequence.
We found 6 miRNAs (miR-10a-5p, miR-142a-5p, miR-
146a-5p, miR-155-5p, miR-211-5p and miR-455-5p) to be
commonly deregulated between APPtg and TAUtg mice
and 4 of these (miR-142a-5p, miR-146a-5p, miR-155-5p
and miR-455-5p) were upregulated in AD patients [40, 41,
43, 44, 53]. Upregulation of miR-142a-5p, miR-146a-5p
and miR-155-5p has also been found in brains of patients
Fig. 3 Gene ontology (GO) enrichment analysis on predicted targets of each upregulated miRNA. Numbers between brackets are the number of
genes within each GO category or the number of predicted targets for each miRNA. Colors represent the enrichment score and only significantly
enriched GO terms/miRNA target combinations are depicted (FDR-corrected p-value< 0.05). Numbers within each cell represent the number of
predicted targets that fall into each GO category. No significant enrichment is observed for the predicted targets of miR-455-5p, which is therefore
excluded from the heatmap
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with other neurological illnesses presenting with neuroin-
flammation and cognitive impairment, including Down’s
syndrome, multiple sclerose, amyotrophic lateral sclerosis,
virus-induced encephalitis and temporal lobe epilepsy pa-
tients [54–62].
It has been suggested that increases in the expression
of miR-142a-5p, miR-146a-5p and miR-155-5p in pa-
tients and mouse models of neurodegeneration are due
to a combination of disease-associated gliosis and glial
expression of these miRNAs, although in situ evidence
of glial expression of these miRNAs is lacking [55, 59,
63, 64]. Our ISH data, alternatively, suggest these ‘glia-s-
pecific’ miRNAs miR-142a-5p, miR-155-5p and miR-
146a-5p are in fact mainly expressed in neurons [34, 60,
62, 65], with minimal expression in astrocytes and
microglia, making it unlikely that the upregulated
Fig. 4 miRNA overexpression does not induce robust cognitive deficits in WT mice. a) Outline of behavioral study. Male mice (C57BL/6 J, 18–
26 weeks ol, n = 9–12 per treatment group) were stereotactically implanted with an intracerebroventricular guide cannula and injected 1× per
week with either a miR-mimic to overexpress individual miRNAs (3wk scheme), a mix of 6 miR-mimics (miR-mix; 7wk scheme) or negative control
oligonucleotide (Ctrl). b) Mean fold change (SEM) compared to equimolar control oligonucleotide of miRNAs in the hippocampus after individual
miRNA or miR-mix overexpression. c-e) Overexpression of individual miRNAs does not induce changes in cued or contextual conditioned fear
responses. f) Path length in the MWM to find the submerged platform over 10 training days. MiR-mix treatment did not induce significant differences
in learning ability. g) MiR-mix treatment does not affect cued or contextual conditioned fear response. OE: overexpression; wk.: week; OF: open field
test; CFR: conditioned fear response; MWM: Morris water maze; NOR: novel object recognition test; SPSN: social preference/social novelty test
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miRNA expression in our mice is from glial origin. Given
the responsiveness of miR-146a-5p and miR-155-5p miR-
NAs to inflammatory factors such as NF-κB [66, 67], and
NF-κB also being expressed in neurons [68], it could be
speculated that the progressive neuroinflammation in
these neurodegenerative mouse models induces neuronal
expression of these miRNAs. Given the loss of neurons in
patients with AD and in our TAUtg mouse model from
12 M onwards, the increased miRNA levels are real and
not caused by changes in cell numbers. Single cell miRNA
sequencing techniques are not yet readily available, but
once those are developed, these will shed additional light
on cell-type specific miRNA and target interactions in
healthy and diseased conditions.
In the behavioral experiment we aimed to phenocopy
the AD-like hippocampus-dependent deficits of our
mouse models in WT mice, by overexpressing the 6
deregulated miRNAs either individually or in a mix. Nei-
ther treatment regimen induced robust cognitive deficits
in WT mice, indicating that the identified miRNAs are
not directly responsible for the disease process. It is diffi-
cult to interpret negative data, raising questions regarding
the frequency and efficiency of miR-mimic delivery and
their functional effect. Yet our titration experiment for
dose determination demonstrates good dose-response
curves and/or decreasing overexpression levels over time
for all the miR-mimic treatments (see Additional file 2:
Figure S1), demonstrating the technical feasibility of such
infusion experiments. Indeed, both overexpression and
downregulation studies in WTand TG mice have success-
fully been used in the past with the same delivery route
and compounds to phenocopy or rescue various aspects
of AD-related neurodegeneration or behavioral deficits
[31, 69–71]. Thus our original hypothesis that these com-
mon upregulated microRNA are involved in the conver-
ging memory declining phenotype in these mice models,
does not hold. Additional studies are now needed to in-
vestigate the alternative hypothesis, i.e. whether downreg-
ulating the miRNA using anti-miR oligonucleotides, in the
AD model mice would aggravate their phenotypes.
It should be noted that the identified miRNAs have
among their predicted targets several AD relevant pro-
teins involved in Abeta generation (e.g. Aph1a, Aph1b)
or TAU kinases (e.g. Gsk3β, Cdk5, Camk2a), phospha-
tases (e.g. Pten, Ppp2ca) and protein TAU itself (see
Additional file 1: Table S4). Since the levels of (some)
miRNAs correlate with increasing pathology load (see
Additional file 3: Figure S2B&E), one is tempted to
speculate that upregulation of these miRNAs may indeed
exert a protective effect, i.e. dampen pathology. Further
work is needed to investigate whether even stronger or
earlier overexpression of these miRNAs in neurodegen-
eration mouse models might have a protective effect on
the progression of AD-related pathology in these mice.
Conclusions
The current study identified 6 miRNAs that become up-
regulated in 2 mouse models of neurodegeneration, 4 of
which could be confirmed in AD patients. Upregulation
of these miRNAs in WT mice was insufficient to drive
cognitive impairment. It is possible that they contribute
along with other deregulated (post)transcriptional path-
ways to cognitive deficits in AD models, however the
opposite interpretation that these microRNA modulate
pathology load in these mouse models requires further
investigation.
Additional files
Additional file 1: Table S1. Overview of miRNA FISH probes. Table S2.
All significant miRNAs for age/genotype/age*genotype for APPtg and
TAUtg combined, APPtg and TAUtg. Table S3. Predicted targets by
TargetScan Mouse (v.7.1) for the six identifief miRNAs. Table S4. Predicted
targets of miR-10a-5p, miR-142a-5p, miR-146a-5p, miR-155-5p, miR-211-5p
and miR-455-5p that play a role in the production of amyloid-β or TAU
(de)phosphorylation. (XLSX 65 kb)
Additional file 2: Figure S1. Semi-quantitative qPCR data of the titration
study to assess the degree of miRNA expression after various dosages of
miR-mimic oligonucleotide (n = 2 per dose). For each miRNA the level of
overexpression was determined either 1 week after receiving a 150, 75 or
15 pmol dose (green dots), or after 48 h (blue squares) when receiving
either a 15 pmol dose (miR-142a-5, miR-146a-5p), or a 1.5–0.0015 pmol dose
(all others). As expected, overexpression levels of miR-142a-5p and miR-
146a-5p are higher 48 h than 1 week after infusion. Fold changes per dose
are expressed in comparison to the expression levels of the miRNA in
negative control infused mice (see Methods). (PNG 2150 kb)
Additional file 3: Figure S2. Correlation between miRNA expression
and pathology load in APPtg and TAUtg mice and AD patients. A)
Hippocampal levels of soluble and insoluble Aβ40 and Aβ42 levels were
measured by ELISA in APPwt and APPtg mice at 4 M and 10 M of age. 2-
way ANOVA demonstrates significant effects for age, genotype and
age*genotype for all measured Aβ species, with 10 M APPtg mice having
significantly higher expression compared to all other groups. ***:p < 0.001
(Tukey’s post-hoc analysis). B) Spearman correlation with false discovery rate
(FDR) p-value adjustment, demonstrate significant correlations (p < 0.05)
between all miRNAs and all Aβ species. C) Representative western blot of
total TAU and phosphorylated TAU (as measured by AT8 & AT270). D)
Quantification of the blots shown in C), demonstrating significant genotype
effects for both TAU and phosphorylated TAU. Levels of phosphorylated
TAU are normalized to both β-actin as well as to TAU expression levels. E)
Spearman correlation with FDR p-value adjustment between the 6 miRNAs
of interest and levels of TAU protein and phosphorylated TAU. The correlation
coefficient is only stated in the cells of the table if it was statistically significant
(p < 0.05), otherwise the cell reads ‘0’. F) Spearman correlation with FDR p-
value adjustment between the qPCR-based expression levels of the 5
expressed miRNAs in human tissue and the protein levels of TAU,
phosphorylated TAU (AT8 & AT270), full length APP (flAPP), soluble
APPβ (sAPPbeta) and APP c-terminal fragments (CTFs) as measured
by western blotting in [31]. Only cells with significant (p < 0.05) correlations
state the correlation coefficient, the others read ‘0’. (PNG 3343 kb)
Additional file 4: Figure S3. Significantly differentially expressed miRNAs
after statistical assessment of age*genotype interaction (int), age and
genotype (gen) in APPtg and TAUtg mice combined (all) and separate.
Colors represent log2(fold change) and only statistically significant
(padj< 0.05) miRNAs are depicted. (PNG 2826 kb)
Additional file 5: Figure S4. Behavioral assessment after
intracerebroventricular injections of individual or a mix of 6 miR-mimic
oligos (miR-mix), or negative control (Ctrl). A) miRNA overexpression does
not induce changes in locomotor behavior as measured by the total dis-
tance moved in the open field arena. B) MiR-mimic treatment does not
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affect anxiety-like behavior, as measured by the amount of time spent in
the centre and corners of the open field arena. C) MiR-mimic treated
groups do not differentiate better between novel and familiar arm than
the control-treated group in the T-maze. D) After 10 days of training,
both control and miR-mix-treated mice spend significantly more time in
the target quadrant of the Morris Water Maze (one-sample t-test against
25 s, **, p < 0.01). E) Although both treatment groups spent significantly
more time with the stranger mouse (Str1) than close to the empty cage
in the Social Preference/Social Novelty test (one-sample t-test against
50%, **, p < 0.01), both do not differentiate between the novel (StrNov)
and the familiar stranger (StrFam). F) Both control and miR-mix-treated
mice spend significantly more time with the novel than the familiar
object (one-sample t-test against 0, *, p < 0.05, **, p < 0.01). (PNG 3027 kb)
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